Abstract
BACKGROUND
The current study describes the results of a double blind, placeboβcontrolled, randomized, single crossover trial of the treatment of patients with postmastectomy lymphedema (PML) with lowβlevel laser therapy (LLLT).
METHODS
Participants received placebo or one cycle or two cycles of LLLT to the axillary region of their affected arm. They were monitored for reductions in affected limb volume, upper body extracellular tissue fluid distribution, dermal tonometry, and range of limb movement.
RESULTS
There was no significant improvement reported immediately after any of the treatments. However, the mean affected limb volume was found to be significantly reduced at 1 month or 3 months of followβup after 2 cycles of active laser treatment. Approximately 31% of subjects had a clinically significant reduction in the volume of their PMLβaffected arm (> 200 mLs) approximately 2β3 months after 2 cycles of treatment. There was no significant effect of placebo treatment, or one cycle of laser treatment, on affected limb volume. The extracellular fluid index of the affected and unaffected arms and torso were reported to be significantly reduced at 3 months after 2 cycles of laser therapy, and there was significant softening of the tissues in the affected upper arm. Treatment did not appear to improve range of movement of the affected arm.
CONCLUSIONS
Two cycles of laser treatment were found to be effective in reducing the volume of the affected arm, extracellular fluid, and tissue hardness in approximately 33% of patients with postmastectomy lymphedema at 3 months after treatment. Cancer 2003;98:1114β22. Β© 2003 American Cancer Society.
DOI 10.1002/cncr.11641